CURRENT DEVELOPMENT OF PODOPHYLLOTOXINS

[1] ABELOFF MD, 1979, CANCER TREAT REP, V63, P519

[2] AISNER J, 1980, P AM ASSOC CANC RES, V21, P453

[3] ARNOLD AM, 1979, CANCER CHEMOTH PHARM, V3, P71

[4] ARNOLD AM, 1980, CANCER CHEMOTHER P S, V5, P2

[5] BEVERIDGE T, 1974, BIOAVAILABILITY STUD

[6] BLEYER WA, 1978, P AM ASSOC CANC RES, V19, P373

[7] BLEYER WA, 1979, CANCER TREAT REP, V63, P977

[8] BRODEN LE, 1979, P AM ASSOC CANC RES, V20, P278

[9] BRUNNER KW, 1976, CANCER TREAT REP, V60, P1377

[10] STUDIES OF CROSS-RESISTANCE, SYNERGISTIC COMBINATIONS AND BLOCKING OF ACTIVITY OF PLATINUM DERIVATIVES [J]. BIOCHIMIE, 1978, 60 (09) : 961 - 965

[1] ABELOFF MD, 1979, CANCER TREAT REP, V63, P519

[2] AISNER J, 1980, P AM ASSOC CANC RES, V21, P453

[3] ARNOLD AM, 1979, CANCER CHEMOTH PHARM, V3, P71

[4] ARNOLD AM, 1980, CANCER CHEMOTHER P S, V5, P2

[5] BEVERIDGE T, 1974, BIOAVAILABILITY STUD

[6] BLEYER WA, 1978, P AM ASSOC CANC RES, V19, P373

[7] BLEYER WA, 1979, CANCER TREAT REP, V63, P977

[8] BRODEN LE, 1979, P AM ASSOC CANC RES, V20, P278

[9] BRUNNER KW, 1976, CANCER TREAT REP, V60, P1377

[10] STUDIES OF CROSS-RESISTANCE, SYNERGISTIC COMBINATIONS AND BLOCKING OF ACTIVITY OF PLATINUM DERIVATIVES [J]. BIOCHIMIE, 1978, 60 (09) : 961 - 965